BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Hastings, S., Myles, P. S., & Medcalf, R. L. (2021). Plasmin, immunity, and surgical site infection. Journal of Clinical Medicine, 10(10). Added by: Dr. Enrique Feoli (22/10/2023, 19:27) Last edited by: Dr. Enrique Feoli (22/10/2023, 19:28) |
 |
| Resource type: Journal Article DOI: 10.3390/jcm10102070 ID no. (ISBN etc.): 2077-0383 BibTeX citation key: Hastings2021 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: Heridas quirúrgicas Creators: Hastings, Medcalf, Myles Collection: Journal of Clinical Medicine |
Views: 1/72
|
| Abstract |
|
SSI are a universal economic burden and increase individual patient morbidity and mortality. While antibiotic prophylaxis is the primary preventative intervention, these agents are not themselves benign and may be less effective in the context of emerging antibiotic resistant organisms. Exploration of novel therapies as an adjunct to antimicrobials is warranted. Plasmin and the plasminogen activating system has a complex role in immune function. The immunothrombotic role of plasmin is densely interwoven with the coagulation system and has a multitude of effects on the immune system constituents, which may not always be beneficial. Tranexamic acid is an antifibrinolytic agent which inhibits the conversion of plasminogen to plasmin. Clinical trials have demonstrated a reduction in surgical site infection in TXA exposed patients, however the mechanism and magnitude of this benefit is incompletely understood. This effect may be through the reduction of local wound haematoma, decreased allogenic blood transfusion or a direct immunomodulatory effect. Large scale randomised clinical trial are currently being undertaken to better explain this association. Importantly, TXA is a safe and widely available pharmacological agent which may have a role in the reduction of SSI.
|